Interferon Alfa-2b for recurrent and metastatic giant cell tumor of the spine: Report of two cases

Spine

Volumn 35, Issue 24, 2010, Pages

  Wei, Feng ^a   Liu, Xiaoguang ^a   Liu, Zhongjun ^a   Jiang, Liang ^a   Dang, Gengting ^a   Ma, Qingjun ^a   Dang, Lei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

angiogenesis; giant cell tumor of spine; interferon alfa 2b; metastasis; multicentric; recurrence

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; EPIRUBICIN;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GIANT CELL TUMOR; HUMAN; LEUKOPENIA; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPINAL CORD COMPRESSION; SPINE SCINTISCANNING; SPINE SURGERY; SPINE TUMOR; THORAX RADIOGRAPHY; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS; BIOPSY; FEMALE; GIANT CELL TUMOR OF BONE; HUMANS; INTERFERON ALFA-2B; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; SPINAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649450006     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181e7bf5a     Document Type: Article

References (27)

1. Hart RA, Boriani S, Biagini R, et al. A system for surgical staging and management of spine tumors: a clinical outcome study of giant cell tumors of the spine. Spine 1997;22:1773-83.
2. Fidler MW. Surgical treatment of giant cell tumours of the thoracic and lumbar spine: report of nine patients. Eur Spine J 2001;10:69-77.
3. Junming M, Cheng Y, Dong C, et al. Giant cell tumor of the cervical spine: a series of 22 cases and outcomes. Spine 2008;33:280-8.
4. Brouty-Boye D, Zetter B. Inhibition of cell motility by interferon. Science 1980;208:516-8.
5. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res 1987;47: 5155-61.
6. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989; 81:497-502.
7. Kaban LB, Mulliken JB, Ezekowitz RA, et al. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999;103:1145-9.
8. Kaiser U, Neumann K, Havemann K. Generalized giant-cell tumour of bone: successful treatment of pulmonary metastases with interferon alpha: a case report. J Cancer Res Clin Oncol 1993;119:301-3.
9. Strander H, Boethius J, Erhardt K. Does successful interferon treatment of tumor patients require life-long treatment? J Interferon Res 1987;7:619-26.
10. Dianzani F, Antonelli G. Mechanism of action of the interferons: biological basis. In: Stuart-Harris R, Penny R, eds. The Clinical Applications of the Interferons. London, United Kingdom: Chapman & Hall Medical; 1997: 255-65.
11. Jonasch E, Kumar U, Linette G, et al. Adjuvant high-dose interferon alfa-2b in patients with high risk melanoma. Cancer J Sci Am 2000;6:132-4.
12. Kirkwood J, Ibrahim J, Sosman J, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected Stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;9:2370-80.
13. Fleischmann W, Fleischmann C. Mechanism of interferon's antitumor actions. In: Baron S, Coppenhaver D, Dianzini F, eds. Interferon: Principles and Medical Applications. Galveston, TX: University of Texas Medical Branch; 1992:299-310.
14. Singh R, Gutman M, Bucana CD, et al. Interferons alfa and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-6.
15. Dinney C, Bielenberg D, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis and growth of human bladder carcinoma in mice by systemic interferon-alfa administration. Cancer Res 1998; 58:808-14.
16. White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320:1197-200.
17. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989;320:1211-2.
18. Kaban LB, Troulis MJ, Ebb D, et al. Antiangiogenic therapy with inter-feron alfa for giant cell lesions of the jaws. Oral Maxillofac Surg 2002; 60:1103-11.
19. Pogrel MA, Harris ST, Regezi J, et al. Calcitonin therapy for central giant cell granulomas [abstract]. J Oral Maxillofac Surg 1997;55(suppl):38.
20. Dahlin DC, Unni KK. Bone Tumors: General Aspects and Data on 8542 Cases. 4th ed. Springfield, MA: Charles C Thomas; 1986:119-40.
21. Feldman F. Case report 115. Skeletal Radiol 1980;5:119-26.
22. Peimer CA, Schiller AL, Mankin HJ, et al. Multicentric giant cell tumor of bone. J Bone Joint Surg Am 1980;62:652-6.
23. Sim FH, Dahlin DC, Beabout JW. Multicentric giant cell tumor of bone. J Bone Joint Surg Am 1977;59:1052-60.
24. Kos CB, Taconis WK, Fidler MW, et al. Multifocal giant cell tumors in the spine. A case report. Spine 1997;22:821-2.
25. Mlszczyk L, Horzela A, Wozniak G, et al. Multicentric giant cell tumour. The case report. Przegl Lek 2004;61:1455-8.
26. Cummins CA, Scarborough MT, Enneking WF. Multicentric giant cell tumor of bone. Clin Orthop Relat Res 1996;322:245-52.
27. Batson OV. The function of the vertebral veins and their role in the spread of metastases. 1940. Clin Orthop Relat Res 1995;312:4-9.